These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 11792188)

  • 1. Preparation and functional evaluation of RGD-modified proteins as alpha(v)beta(3) integrin directed therapeutics.
    Kok RJ; Schraa AJ; Bos EJ; Moorlag HE; Asgeirsdóttir SA; Everts M; Meijer DK; Molema G
    Bioconjug Chem; 2002; 13(1):128-35. PubMed ID: 11792188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endothelial cells internalize and degrade RGD-modified proteins developed for tumor vasculature targeting.
    Schraa AJ; Kok RJ; Berendsen AD; Moorlag HE; Bos EJ; Meijer DK; de Leij LF; Molema G
    J Control Release; 2002 Oct; 83(2):241-51. PubMed ID: 12363450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of In-Labeled Cyclic RGD Peptides: Effects of Peptide and Linker Multiplicity on Their Tumor Uptake, Excretion Kinetics and Metabolic Stability.
    Shi J; Zhou Y; Chakraborty S; Kim YS; Jia B; Wang F; Liu S
    Theranostics; 2011; 1():322-40. PubMed ID: 21850213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RGD-modified anti-CD3 antibodies redirect cytolytic capacity of cytotoxic T lymphocytes toward alphavbeta3-expressing endothelial cells.
    Schraa AJ; Kok RJ; Botter SM; Withoff S; Meijer DK; de Leij LF; Molema G
    Int J Cancer; 2004 Nov; 112(2):279-85. PubMed ID: 15352041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting of RGD-modified proteins to tumor vasculature: a pharmacokinetic and cellular distribution study.
    Schraa AJ; Kok RJ; Moorlag HE; Bos EJ; Proost JH; Meijer DK; de Leij LF; Molema G
    Int J Cancer; 2002 Dec; 102(5):469-75. PubMed ID: 12432548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two RGD-independent alpha vbeta 3 integrin binding sites on tumstatin regulate distinct anti-tumor properties.
    Maeshima Y; Colorado PC; Kalluri R
    J Biol Chem; 2000 Aug; 275(31):23745-50. PubMed ID: 10837460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro and in vivo evaluation of a paclitaxel conjugate with the divalent peptide E-[c(RGDfK)2] that targets integrin alpha v beta 3.
    Ryppa C; Mann-Steinberg H; Biniossek ML; Satchi-Fainaro R; Kratz F
    Int J Pharm; 2009 Feb; 368(1-2):89-97. PubMed ID: 18992308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrins alpha(v)beta3 and alpha(v)beta5 are expressed by endothelium of high-risk neuroblastoma and their inhibition is associated with increased endogenous ceramide.
    Erdreich-Epstein A; Shimada H; Groshen S; Liu M; Metelitsa LS; Kim KS; Stins MF; Seeger RC; Durden DL
    Cancer Res; 2000 Feb; 60(3):712-21. PubMed ID: 10676658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Click-chemistry-derived triazole ligands of arginine-glycine-aspartate (RGD) integrins with a broad capacity to inhibit adhesion of melanoma cells and both in vitro and in vivo angiogenesis.
    Trabocchi A; Menchi G; Cini N; Bianchini F; Raspanti S; Bottoncetti A; Pupi A; Calorini L; Guarna A
    J Med Chem; 2010 Oct; 53(19):7119-28. PubMed ID: 20809642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ligands for mapping alphavbeta3-integrin expression in vivo.
    Schottelius M; Laufer B; Kessler H; Wester HJ
    Acc Chem Res; 2009 Jul; 42(7):969-80. PubMed ID: 19489579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bicyclic RGD peptides with high integrin α
    Cipriani F; Bernhagen D; García-Arévalo C; de Torre IG; Timmerman P; Rodríguez-Cabello JC
    Biomed Mater; 2019 Mar; 14(3):035009. PubMed ID: 30630151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clustering of vitronectin and RGD peptides on microspheres leads to engagement of integrins on the luminal aspect of endothelial cell membrane.
    Zanetti A; Conforti G; Hess S; Martìn-Padura I; Ghibaudi E; Preissner KT; Dejana E
    Blood; 1994 Aug; 84(4):1116-23. PubMed ID: 7519474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. On the mode of action of thrombin-induced angiogenesis: thrombin peptide, TP508, mediates effects in endothelial cells via alphavbeta3 integrin.
    Tsopanoglou NE; Papaconstantinou ME; Flordellis CS; Maragoudakis ME
    Thromb Haemost; 2004 Oct; 92(4):846-57. PubMed ID: 15467917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phage libraries displaying cyclic peptides with different ring sizes: ligand specificities of the RGD-directed integrins.
    Koivunen E; Wang B; Ruoslahti E
    Biotechnology (N Y); 1995 Mar; 13(3):265-70. PubMed ID: 9634769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An RGD spacing of 440 nm is sufficient for integrin alpha V beta 3-mediated fibroblast spreading and 140 nm for focal contact and stress fiber formation.
    Massia SP; Hubbell JA
    J Cell Biol; 1991 Sep; 114(5):1089-100. PubMed ID: 1714913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrin-binding peptides containing RGD produce coronary arteriolar dilation via cyclooxygenase activation.
    Hein TW; Platts SH; Waitkus-Edwards KR; Kuo L; Mousa SA; Meininger GA
    Am J Physiol Heart Circ Physiol; 2001 Dec; 281(6):H2378-84. PubMed ID: 11709402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multivalent effects of RGD peptides obtained by nanoparticle display.
    Montet X; Funovics M; Montet-Abou K; Weissleder R; Josephson L
    J Med Chem; 2006 Oct; 49(20):6087-93. PubMed ID: 17004722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of angiogenesis and tumor growth by SCH221153, a dual alpha(v)beta3 and alpha(v)beta5 integrin receptor antagonist.
    Kumar CC; Malkowski M; Yin Z; Tanghetti E; Yaremko B; Nechuta T; Varner J; Liu M; Smith EM; Neustadt B; Presta M; Armstrong L
    Cancer Res; 2001 Mar; 61(5):2232-8. PubMed ID: 11280792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Site-specific inhibition of integrin alpha v beta 3-vitronectin association by a ser-asp-val sequence through an Arg-Gly-Asp-binding site of the integrin.
    Choi Y; Kim E; Lee Y; Han MH; Kang IC
    Proteomics; 2010 Jan; 10(1):72-80. PubMed ID: 19882657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of angiogenesis in vitro and in vivo: comparison of the relative activities of triflavin, an Arg-Gly-Asp-containing peptide and anti-alpha(v)beta3 integrin monoclonal antibody.
    Sheu JR; Yen MH; Kan YC; Hung WC; Chang PT; Luk HN
    Biochim Biophys Acta; 1997 Oct; 1336(3):445-54. PubMed ID: 9367172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.